Clinical Professor Catherine Stedman

Stedman, C. A. M., Downes, M., & Liddle, C. (2010). Signaling pathways in liver disease: PXR and CAR. In J.-F. Dufour & P.-A. Clavien (Eds.), Signaling pathways in liver disease. (2nd ed.) (pp. 333-343). Berlin: Springer. doi: 10.1007/978-3-642-00150-5_22

Chapter in Book - Research

Liddle, C., & Stedman, C. A. M. (2007). Hepatic metabolism of drugs. In J. Rodes, J.-P. Benhamou, A. Blei, J. Reichen & M. Rizzetto (Eds.), Textbook of hepatology: From basic science to clinical practice. (3rd ed.) (pp. 241-249). Malden, MA: Blackwell.

Chapter in Book - Research

Cheng, Q., Cunningham, E. B., Shih, S., Amin, J., Bruneau, J., Artenie, A. A., … Stedman, C., … on behalf of the SIMPLIFY and D3FEAT Study Groups. (2023). Patient reported outcomes during and following HCV direct-acting antiviral treatment among people who inject drugs. Value in Health. Advance online publication. doi: 10.1016/j.jval.2022.12.016

Journal - Research Article

Cunningham, E. B., Hajarizadeh, B., Amin, J., Hellard, M., Bruneau, J., Felderhof, J. J., … Stedman, C., … on behalf of the SIMPLIFY and D3FEAT Study Groups. (2021). Reinfection following successful direct-acting antiviral therapy for hepatitis C infection among people who inject drugs. Clinical Infectious Diseases, 72(8), 1392-1400. doi: 10.1093/cid/ciaa253

Journal - Research Article

Lamba, M., Ngu, J. H., & Stedman, C. A. M. (2021). Trends in incidence of autoimmune liver diseases and increasing incidence of autoimmune hepatitis. Clinical Gastroenterology & Hepatology, 19(3), 573-579.e1. doi: 10.1016/j.cgh.2020.05.061

Journal - Research Article

Artenie, A. A., Cunningham, E. B., Dore, G. J., Conway, B., Dalgard, O., Powis, J., … Stedman, C., … Grebely, J. (2020). Patterns of drug, alcohol use and injection equipment sharing among people with recent injecting drug use or receiving opioid agonist treatment during and following hepatitis C virus treatment with direct-acting antiviral therapies: An international study. Clinical Infectious Diseases, 70(11), 2369-2376. doi: 10.1093/cid/ciz633

Journal - Research Article

Wade, A. J., Doyle, J. S., Gane, E., Stedman, C., Draper, B., Iser, D., … Hellard, M. E. (2020). Outcomes of treatment for hepatitis C in primary care compared to hospital-based care: A randomized, controlled trial in people who inject drugs. Clinical Infectious Diseases, 70(9), 1900-1906. doi: 10.1093/cid/ciz546

Journal - Research Article

Gane, E., Poordad, F., Zadeikis, N., Valdes, J., Lin, C.-W., Liu, W., … Stedman, C., … Mensa, F. J. (2019). Safety and pharmacokinetics of glecaprevir/pibrentasvir in adults with chronic genotype 1-6 hepatitis C virus infections and compensated liver disease. Clinical Infectious Diseases, 69(10), 1657-1664. doi: 10.1093/cid/ciz022

Journal - Research Article

Gane, E. J., Stedman, C. A., Schwabe, C., Vijgen, L., Chanda, S., Kakuda, T. N., … McClure, M. W. (2018). Short duration AL-335, odalasvir, with or without simeprevir, in patients with HCV GT1 or 3 infection without cirrhosis. Hepatology, 68(6), 2145-2157. doi: 10.1002/hep.30126

Journal - Research Article

Grebely, J., Conway, B., Cunningham, E. B., Fraser, C., Moriggia, A., Gane, E., Stedman, C., … on behalf of the D3FEAT Study Group. (2018). Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy. International Journal of Drug Policy, 62, 94-103. doi: 10.1016/j.drugpo.2018.10.004

Journal - Research Article

Meijer, B., van Everdingen, C. K., Ramsoekh, D., Stedman, C., Frampton, C. M. A., Mulder, C. J. J., … Gearry, R. B. (2018). Transient elastography to assess liver stiffness in patients with inflammatory bowel disease. Digestive & Liver Disease, 50(1), 48-53. doi: 10.1016/j.dld.2017.09.128

Journal - Research Article

Polaris Observatory Collaborators, including Stedman, C. (2018). Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: A modelling study. Lancet Gastroenterology & Hepatology, 3(6), 383-403. doi: 10.1016/S2468-1253(18)30056-6

Journal - Research Article

Zeuzem, S., Foster, G. R., Wang, S., Asatryan, A., Gane, E., Feld, J. J., … Stedman, C. A., … Mensa, F. J. (2018). Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection. New England Journal of Medicine, 378(4), 354-369. doi: 10.1056/NEJMoa1702417

Journal - Research Article

Gane, E. J., Hyland, R. H., Yang, Y., Svarovskaia, E., Stamm, L. M., Brainard, D. M., … Stedman, C. A. M. (2017). Efficacy of ledipasvir plus sofosbuvir for 8 or 12 weeks in patients with hepatitis C virus genotype 2 infection. Gastroenterology, 152(6), 1366-1371. doi: 10.1053/j.gastro.2017.01.017

Journal - Research Article

Gane, E. J., Metivier, S., Nahass, R., Ryan, M., Stedman, C. A., Svarovskaia, E. S., … Lawitz, E. (2017). The emergence of NS5B resistance associated substitution S282T after sofosbuvir-based treatment. Hepatology Communications, 1(6), 538-549. doi: 10.1002/hep4.1060

Journal - Research Article

Gane, E. J., Shiffman, M. L., Etzkorn, K., Morelli, G., Stedman, C. A. M., Davis, M. N., … and the GS-US-342-1553 Investigators. (2017). Sofosbuvir-velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct-acting antiviral regimen. Hepatology, 66(4), 1083-1089. doi: 10.1002/hep.29256

Journal - Research Article

Gane, E., Stedman, C., Dole, K., Chen, J., Meyers, C. D., Wiedmann, B., … Colvin, R. A. (2017). A diacylglycerol transferase 1 inhibitor is a potent hepatitis C antiviral in vitro but not in patients in a randomized clinical trial. ACS Infectious Diseases, 3(2), 144-151. doi: 10.1021/acsinfecdis.6b00138

Journal - Research Article

Jacobson, I. M., Lawitz, E., Gane, E. J., Willems, B. E., Ruane, P. J., Nahass, R. G., … Stedman, C. A. M., … Foster, G. R. (2017). Efficacy of 8 weeks of sofosbuvir, velpatasvir, and voxilaprevir In patients with chronic HCV infection: 2 phase 3 randomized trials. Gastroenterology, 153(1), 113-122. doi: 10.1053/j.gastro.2017.03.047

Journal - Research Article

The Polaris Observatory HCV Collaborators, including Brunton, C. R., & Stedman, C. (2017). Global prevalence and genotype distribution of hepatitis C virus infection in 2015: A modelling study. Lancet Gastroenterology & Hepatology, 2(3), 161-176. doi: 10.1016/S2468-1253(16)30181-9

Journal - Research Article

Gane, E. J., Kowdley, K. V., Pound, D., Stedman, C. A. M., Davis, M., Etzkorn, K., … Nguyen, M. H. (2016). Efficacy of sofosbuvir, velpatasvir, and GS-9857 in patients with hepatitis C virus genotype 2, 3, 4, or 6 infections in an open-label, phase 2 trial. Gastroenterology, 151(5), 902-909. doi: 10.1053/j.gastro.2016.07.038

Journal - Research Article

Gane, E. J., Rouzier, R., Hassanein, T., Stedman, C. A., Mazur, W., Kupcova, V., … Thommes, J. (2016). Ritonavir-boosted danoprevir-based regimens in treatment-naive and prior null responders with HCV genotype 1 or 4 and compensated cirrhosis. Hepatology International, 10(3), 478-487. doi: 10.1007/s12072-015-9699-9

Journal - Research Article

Gane, E. J., Schwabe, C., Hyland, R. H., Yang, Y., Svarovskaia, E., Stamm, L. M., … Stedman, C. A. (2016). Efficacy of the combination of sofosbuvir, velpatasvir, and the NS3/4A protease inhibitor GS-9857 in treatment-naïve or previously treated patients with HCV genotype 1 or 3 infections. Gastroenterology, 151(3), 448-456. doi: 10.1053/j.gastro.2016.05.021

Journal - Research Article

Stedman, C. A. M., Hyland, R. H., Ding, X., Pang, P. S., McHutchison, J. G., & Gane, E. J. (2016). Once daily ledipasvir/sofosbuvir fixed-dose combination with ribavirin in patients with inherited bleeding disorders and hepatitis C genotype 1 infection. Haemophilia, 22(2), 214. doi: 10.1111/hae.12791

Journal - Research Article

Foster, G. R., Afdhal, N., Roberts, S. K., Bräu, N., Gane, E. J., Pianko, S., … Stedman, C. A. M., … Sulkowski, M. (2015). Sofosbuvir and Velpatasvir for HCV genotype 2 and 3 infection. New England Journal of Medicine, 373(27), 2608-2617. doi: 10.1056/NEJMoa1512612

Journal - Research Article

Gane, E. J., Hyland, R. H., An, D., Svarovskaia, E., Pang, P. S., Brainard, D., & Stedman, C. A. (2015). Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection. Gastroenterology, 149, 1454-1461. doi: 10.1053/j.gastro.2015.07.063

Journal - Research Article

Gane, E., Kershenobich, D., Seguin-Devaux, C., Kristiansen, P., Aho, I., Dalgard, O., … Brunton, C. R., … Stedman, C., … Estes, C. (2015). Strategies to manage hepatitis C virus (HCV) infection disease burden: Volume 2. Journal of Viral Hepatitis, 22(Suppl. 1), 46-73. doi: 10.1111/jvh.12352

Journal - Research Article

Hatzakis, A., Chulanov, V., Gadano, A. C., Bergin, C., Ben-Ari, Z., Mossong, J., … Brunton, C. R., … Stedman, C., … Razavi, H. (2015). The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm: Volume 2. Journal of Viral Hepatitis, 22(Suppl. 1), 26-45. doi: 10.1111/jvh.12351

Journal - Research Article

Naggie, S., Cooper, C., Saag, M., Workowski, K., Ruane, P., Towner, W. J., … Stedman, C. A. M., … for the ION-4 Investigators. (2015). Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. New England Journal of Medicine, 373(8), 705-713. doi: 10.1056/NEJMoa1501315

Journal - Research Article

Pianko, S., Flamm, S. L., Shiffman, M. L., Kumar, S., Strasser, S. I., Dore, G. J., … Stedman, C. A. M., … Roberts, S. K. (2015). Sofosbuvir plus velpatasvir combination therapy for treatment: Experienced patients with genotype 1 or 3 hepatitis c virus infection: A randomized trial. Annals of Internal Medicine, 163(11), 809-817. doi: 10.7326/M15-1014

Journal - Research Article

Saraswat, V., Norris, S., de Kneft, R. J., Sanchez Avila, J. F., Sonderup, M., Zuckerman, E., … Stedman, C., … Brunton, C. R., … Gower, E. (2015). Historical epidemiology of hepatitis C virus (HCV) in select countries: Volume 2. Journal of Viral Hepatitis, 22(Suppl. 1), 6-25. doi: 10.1111/jvh.12350

Journal - Research Article

Gane, E. J., Stedman, C. A., Hyland, R. H., Ding, X., Svarovskaia, E., Subramanian, G. M., … Pang, P. S. (2014). Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection. Gastroenterology, 146(3), 736-743. doi: 10.1053/j.gastro.2013.11.007

Journal - Research Article

Gane, E., Stedman, C., Brunton, C., Radke, S., Henderson, C., Estes, C., & Razavi, H. (2014). Impact of improved treatment on disease burden of chronic hepatitis C in New Zealand. New Zealand Medical Journal, 127(1407). Retrieved from http://www.nzma.org.nz/journal

Journal - Research Article

Stedman, C. (2014). Sofosbuvir, a NS5B polymerase inhibitor in the treatment of hepatitis C: A review of its clinical potential. Therapeutic Advances in Gastroenterology, 7(3), 131-140. doi: 10.1177/1756283x13515825

Journal - Research Article

Gane, E. J., Stedman, C. A., Hyland, R. H., Ding, X., Svarovskaia, E., Symonds, W. T., … Berrey, M. M. (2013). Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. New England Journal of Medicine, 368(1), 34-44. doi: 10.1056/NEJMoa1208953

Journal - Research Article

Ngu, J. H., Gearry, R. B., Frampton, C. M., & Stedman, C. A. M. (2013). Autoimmune hepatitis: The role of environmental risk factors: A population-based study. Hepatology International, 7(3), 869-875. doi: 10.1007/s12072-013-9448-x

Journal - Research Article

Ngu, J. H., Gearry, R. B., Frampton, C. M., & Stedman, C. A. M. (2013). Predictors of poor outcome in patients with autoimmune hepatitis: A population-based study. Hepatology, 57(6), 2399-2406. doi: 10.1002/hep.26290

Journal - Research Article

Ngu, J. H., Wallace, M. C., Merriman, T. R., Gearry, R. B., Stedman, C. A. M., & Roberts, R. L. (2013). Association of the HLA locus and TNF with type I autoimmune hepatitis susceptibility in New Zealand Caucasians. SpringerPlus, 2(1), 355. doi: 10.1186/2193-1801-2-355

Journal - Research Article

Nishimura, T., Hu, Y., Wu, M., Pham, E., Suemizu, H., Elazar, M., … Stedman, C., … Peltz, G. (2013). Using chimeric mice with humanized livers to predict human drug metabolism and a drug-drug interactions. Journal of Pharmacology & Experimental Therapeutics, 344(2), 388-396. doi: 10.1124/jpet.112.198697

Journal - Research Article

Chu, T. W., Kulkarni, R., Gane, E. J., Roberts, S. K., Stedman, C., Angus, P. W., … Shulman, N. S. (2012). Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C. Gastroenterology, 142(4), 790-795. doi: 10.1053/j.gastro.2011.12.057

Journal - Research Article

Ngu, J. H., Gearry, R. B., Frampton, C. M., & Stedman, C. A. M. (2012). Mortality and the risk of malignancy in autoimmune liver diseases: A population-based study in Canterbury, New Zealand. Hepatology, 55(2), 522-529. doi: 10.1002/hep.24743

Journal - Research Article

Ngu, J. H., Gearry, R. B., Wright, A. J., & Stedman, C. A. M. (2012). Low incidence and prevalence of primary biliary cirrhosis in Canterbury, New Zealand: A population-based study. Hepatology International, 6(4), 796-800. doi: 10.1007/s12072-011-9329-0

Journal - Research Article

Gane, E. J., Rouzier, R., Stedman, C., Wiercinska-Drapalo, A., Horban, A., Chang, L., … Tran, J. Q. (2011). Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN α-2a/RBV in hepatitis C patients. Journal of Hepatology, 55, 972-979.

Journal - Research Article

Gardiner, S. J., Gearry, R. B., Burt, M. J., Chalmers-Watson, T., Chapman, B. A., Ross, A. G., Stedman, C. A. M., … Barclay, M. L. (2011). Allopurinol might improve response to azathioprine and 6-mercaptopurine by correcting an unfavorable metabolite ratio. Journal of Gastroenterology & Hepatology, 26(1), 49-54. doi: 10.1111/j.1440-1746.2010.06489.x

Journal - Research Article

Ngu, J. H., Gearry, R. B., Wright, A. J., & Stedman, C. A. M. (2011). Inflammatory bowel disease is associated with poor outcomes of patients with primary sclerosing cholangitis. Clinical Gastroenterology & Hepatology, 9(12), 1092-1097. doi: 10.1016/j.cgh.2011.08.027

Journal - Research Article

Gane, E. J., Roberts, S. K., Stedman, C. A. M., Angus, P. W., Ritchie, B., Elston, R., … Smith, P. F. (2010). Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): A randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet, 376(9751), 1467-1475. doi: 10.1016/s0140-6736(10)61384-0

Journal - Research Article

Ngu, J. H., Bechly, K., Chapman, B. A., Burt, M. J., Barclay, M. L., Gearry, R. B., & Stedman, C. A. M. (2010). Population-based epidemiology study of autoimmune hepatitis: A disease of older women? Journal of Gastroenterology & Hepatology, 25(10), 1681-1686. doi: 10.1111/j.1440-1746.2010.06384.x

Journal - Research Article

Jonker, J. W., Stedman, C. A. M., Liddle, C., & Downes, M. (2009). Hepatobiliary ABC transporters: Physiology, regulation and implications for disease. Frontiers in Bioscience, 14, 4904-4920. doi: 10.2741/3576

Journal - Research Article

Stedman, C., Liddle, C., Coulter, S., Sonoda, J., Alvarez, J. G., Evans, R. M., & Downes, M. (2006). Benefit of farnesoid X receptor inhibition in obstructive cholestasis. PNAS, 103(30), 11323-11328.

Journal - Research Article

Stedman, C. A. M., Liddle, C., Coulter, S. A., Sonoda, J., Alvarez, J. G. A., Moore, D. D., … Downes, M. (2005). Nuclear receptors constitutive androstane receptor and pregnane X receptor ameliorate cholestatic liver injury. PNAS, 102(6), 2063-2068.

Journal - Research Article

Stedman, C., Robertson, G., Coulter, S., & Liddle, C. (2004). Feed-forward regulation of bile acid detoxification by CYP3A4. Journal of Biological Chemistry, 279(12), 11336-11343.

Journal - Research Article

Stedman, C. (2002). Herbal hepatotoxicity. Seminars in Liver Disease, 22(2), 195-206.

Journal - Research Article

Stedman, C. A. M., Begg, E. J., Kennedy, M. A., Roberts, R., & Wilkinson, T. J. (2002). Cytochrome P450 2D6 genotype does not predict SSRI (fluoxetine or paroxetine) induced hyponatraemia. Human Psychopharmacology, 17(4), 187-190.

Journal - Research Article

Walter, T., Connor, S., Stedman, C., & Doogue, M. (2022). A case of acute necrotising pancreatitis following the second dose of Pfizer-BioNTech COVID-19 mRNA vaccine. British Journal of Clinical Pharmacology, 88, 1385-1386. doi: 10.1111/bcp.15039

Journal - Research Other

Tharayil, V. S., Chalmers-Watson, T., Cole, D., & Stedman, C. (2019). Oesophageal tuberculosis: A rare cause of dysphagia. Annals of Clinical Case Reports, 4, 1597. [Case Study].

Journal - Research Other

Wade, A. J., Doyle, J. S., Gane, E., Stedman, C., Draper, B., Iser, D., … Hellard, M. E. (2018). Community-based provision of direct-acting antiviral therapy for hepatitis C: Study protocol and challenges of a randomized controlled trial. Trials, 19, 383. doi: 10.1186/s13063-018-2768-3

Journal - Research Other

Ngu, J. H., Gearry, R. B., & Stedman, C. A. M. (2017). Autoimmune hepatitis in the East and the West. Inflammatory Intestinal Diseases, 1(4), 147-149. doi: 10.1159/000455177

Journal - Research Other

Stedman, C. A. M. (2013). Current prospects for interferon-free treatment of hepatitis C in 2012. Journal of Gastroenterology & Hepatology, 28(1), 38-45. doi: 10.1111/jgh.12028

Journal - Research Other

Ngu, J. H., Gearry, R. B., & Stedman, C. A. M. (2012). Has primary sclerosing cholangitis associated with Crohn's disease a better outcome? Journal of Crohn's & Colitis, 6(9), 956. doi: 10.1016/j.crohns.2012.05.013

Journal - Research Other

Stedman, C. A. M., & Barclay, M. L. (2000). Comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Alimentary Pharmacology & Therapeutics, 14(8), 963-978. doi: 10.1046/j.1365-2036.2000.00788.x

Journal - Research Other